Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Sep 6, 2023
- Accession no.
- 0001447362-23-000138
- Filed
- Sep 6, 2023
- Trade date
- Sep 1, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions. Open-market sales total $30.1K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2023 | Common Stock | SSaleDisposed | −718 | $20.05F2 | −$14,395.9 | 115,103 | Direct | |
| Sep 1, 2023 | Common Stock | SSaleDisposed | −226 | $20.05F2 | −$4,531.3 | 105,853 | Indirect | |
| Sep 1, 2023 | Common Stock | SSaleDisposed | −226 | $20.05F2 | −$4,531.3 | 94,748 | Indirect | |
| Sep 1, 2023 | Common Stock | SSaleDisposed | −81 | $20.05F2 | −$1,624.05 | 16,653 | Indirect | |
| Sep 1, 2023 | Common Stock | SSaleDisposed | −83 | $20.05F2 | −$1,664.15 | 16,652 | Indirect | |
| Sep 1, 2023 | Common Stock | SSaleDisposed | −83 | $20.05F2 | −$1,664.15 | 16,652 | Indirect | |
| Sep 1, 2023 | Common Stock | SSaleDisposed | −83 | $20.05F2 | −$1,664.15 | 16,646 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $20.010 to $20.125, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.